Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Kejia Ding
A Potent Chemotherapeutic Strategy With Eg5 Inhibitor Against Gemcitabine Resistant Bladder Cancer
PLoS ONE
Multidisciplinary
Therapeutic Effect and Adverse Reaction of Sorafenib in the Treatment of Advanced Renal Cancer
Oncology Letters
Cancer Research
Oncology
Related publications
P63 Expression Correlates With Sensitivity to the Eg5 Inhibitor AZD4877 in Bladder Cancer Cells
Cancer Biology and Therapy
Cancer Research
Oncology
Molecular Medicine
Pharmacology
A Pharmacological Strategy Using Stemofoline for More Efficacious Chemotherapeutic Treatments Against Human Multidrug Resistant Leukemic Cells
Asian Pacific Journal of Cancer Prevention
Polycationic Calixarene PTX013, a Potent Cytotoxic Agent Against Tumors and Drug Resistant Cancer
Investigational New Drugs
Oncology
Pharmacology
Targeting Autophagy by MPT0L145, a Highly Potent PIK3C3 Inhibitor, Provides Synergistic Interaction to Targeted or Chemotherapeutic Agents in Cancer Cells
Cancers
Cancer Research
Oncology
Establishment and Characterization of the Gemcitabine‑resistant Human Pancreatic Cancer Cell Line SW1990/gemcitabine
Oncology Letters
Cancer Research
Oncology
ACHN-490, a Neoglycoside With Potent in Vitro Activity Against Multidrug-Resistant Klebsiella Pneumoniae Isolates
Antimicrobial Agents and Chemotherapy
Infectious Diseases
Pharmacology
Aspirin Inhibits Proliferation of Gemcitabine-Resistant Human Pancreatic Cancer Cells and Augments Gemcitabine-Induced Cytotoxicity
Acta Pharmacologica Sinica
Medicine
Pharmacology
A Novel PI3K Inhibitor PIK-C98 Displays Potent Preclinical Activity Against Multiple Myeloma
Oncotarget
Oncology
XPO1 Inhibition by Selinexor Induces Potent Cytotoxicity Against High Grade Bladder Malignancies
Oncotarget
Oncology
